Global MDM2 overexpression does not correlate with disease outcome [674]; however, high-MDM2 score was associated with distant metastasis and mortality in patients treated with radiotherapy and androgen deprivation for prostate cancer [674]. Here, MDM2 is linked to prostate carcinoma.